It found a strong response band of RhoA mRNA was observed after reverse transcription(RT) response from ovarian malignant tumors, while weak response bands were observed in benign or borderline tumors, indicating that the expression level of RhoA mRNA in ovarian malignant tumors was significantly higher than benign and borderline tumors (Horiuchi et al., 2003; Zaoui et al., 2019). This evidence concerns the gene RHOA and ovarian cancer.